Diagnostic value of combined detection of serum AKR1B10 and FGF21 for poor prognosis of HHD
Aim To explore the predictive value of combined detection of serum aldo-keto reductase family 1 member B10(AKR1B10)and fibroblast growth factor 21(FGF21)for poor prognosis in patients with hypertensive heart disease(HHD).Methods 145 patients with HHD in our hospital were selected as the research subjects.At the end of follow-up,based on the pres-ence or absence of major adverse cardiovascular events(MACE),the patients were divided into non-MACE group(84 cases)and MACE group(61 cases).The clinical data and serum levels of AKR1B10 and FGF21 between two groups were compared.The correlation between AKR1B10,and FGF2 levels and poor prognosis in HHD patients was analyzed by Spearman correlation analysis.The factors affecting the adverse prognosis of HHD was analyzed by multivariate Logistic regression.The diagnostic efficacy of serum AKR1B10 and FGF21 combined detection for adverse prognosis in HHD patients was evaluated by ROC.Results Compared with the non-MACE group,the body mass index(BMI),the proportion of hyperlipidemia,left ventricular end diastolic dimension,inter-ventricular septal diameter,left ventricular myocardial mass index and serum AKR1B10 levels were increased in MACE group.The proportion of β-blockers,angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists and FGF21 levels were de-creased(P＜0.05).The adverse prognosis of HHD was positively correlated with AKR1B10(P＜0.001),but negatively correlated with FGF21(P＜0.001).Elevated BMI,type 2 diabetes mellitus,elevated AKR1B10 and decreased FGF21 levels were independent risk factors for poor prognosis in HHD patients.The efficacy of serum AKR1B10 combined with FGF21 is higher than that of single index,and it has high predictive value for poor prognosis of HHD patients.Conclusion Serum AKR1 B10 combined with FGF21 has a high predictive value for poor prognosis in patients with HHD.
万方数据
维普
